Aroa Biosurgery (ASX:ARX) Common Stock : A$134.67 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Common Stock?

Aroa Biosurgery's quarterly common stock declined from Mar. 2023 (A$137.13 Mil) to Sep. 2023 (A$136.20 Mil) and declined from Sep. 2023 (A$136.20 Mil) to Mar. 2024 (A$134.67 Mil).

Aroa Biosurgery's annual common stock increased from Mar. 2022 (A$135.47 Mil) to Mar. 2023 (A$137.13 Mil) but then declined from Mar. 2023 (A$137.13 Mil) to Mar. 2024 (A$134.67 Mil).

Aroa Biosurgery Common Stock Historical Data

The historical data trend for Aroa Biosurgery's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Common Stock Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Common Stock

94.30

89.34

135.47

137.13

134.67

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Common Stock	Get a 7-Day Free Trial			135.47	128.54	137.13	136.20	134.67

Aroa Biosurgery Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines